The UK regulator of psychiatric drugs (the MHRA) is entirely funded by the pharmaceutical industry, and employs ex-industry professionals in key leadership positions. Such conflicts of interest could lead to lenient regulation that places commercial interests above patient protection.
Below is a short PDF statement supporting this unrecognised fact. You may freely download and share this article.